Efficacy and safety of losartan 100 mg or losartan 100 mg plus hydrochlorothiazide 25 mg in the treatment of patients with essential arterial hypertension and CV risk factors: Observational, prospective study in primary care

Current Medical Research and Opinion

Volumn 25, Issue 4, 2009, Pages 981-990

  Bönner, Gerd ^a   Smolka, W ^b   Jung, C ^b   Bestehorn, K ^b  

^a MEDIAN Kliniken GmbH   (Germany)

^b MSD Sharp and Dohme GmbH   (Germany)

Author keywords

Combination; Essential hypertension; Hydrochlorothiazide; Losartan; Risk factors; Tolerability

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CREATININE; DIURETIC AGENT; FORTZAAR; GLUCOSE; HEMOGLOBIN A1C; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; LOSARTAN POTASSIUM; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; ALBUMINURIA; ALOPECIA; ANTIHYPERTENSIVE ACTIVITY; ARTERY DISEASE; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESSENTIAL HYPERTENSION; FEMALE; GLUCOSE BLOOD LEVEL; HEADACHE; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALAISE; MALE; MONOTHERAPY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; OPEN STUDY; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PROSPECTIVE STUDY; PRURITUS; RISK FACTOR; SMOKING; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CREATININE; DIABETES COMPLICATIONS; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; LOSARTAN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SAFETY;

EID: 67649321894     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990902809876     Document Type: Article

References (45)

1. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-2571 (Pubitemid 37430158)
2. Guidelines committee. European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-1053 (Pubitemid 36667855)
3. Mancia G, De Backer G, Dominiczak A, et al. 2007 guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007;28:1462-1536
4. Wittchen HU, Glaesmer H, Marz W, et al. Cardiovascular risk factors in primary care: methods and baseline prevalence rates - the DETECT program. Curr Med Res Opin 2005;21:619-630 (Pubitemid 40676115)
5. Krone W, Böhm M, Wöhrmann A, et al. Erhebung und Verbesserung der Behandlungssituation von Patienten mit Diabetes mellitus. Das DUTY-Register. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 2004;47:540-546
6. Voller H, Sonntag FJ, Thiery J, et al. Management of high-risk patients with hypertension and left ventricular hypertrophy in Germany: differences between cardiac specialists in the inpatient and outpatient setting. BMC Public Health 2006;6:256 (Pubitemid 44664452)
7. Wong ND, Lopez VA, L'Italien G, et al. Inadequate control of hypertension in US adults with cardiovascular disease comorbidities in 2003-2004. Arch Intern Med 2007;167:2431-2436
8. Epstein M, Sowers J. Diabetes mellitus and hypertension. Hypertension 1992;19:403-418
9. Bloomgarden ZT. Diabetes and Hypertension. Diabetes Care 2001;24:1679-1684
10. Parving HH, Lewis JB, Ravid M, et al. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int 2006;69:2057-2063 (Pubitemid 43924271)
11. Wang TJ, Evans JC, Meigs JB, et al. Low-grade albuminuria and the risks of hypertension and blood pressure progression. Circulation 2005;111:1370-1376 (Pubitemid 40396802)
12. Schmieder RE, Schrader J, Zidek W, et al. Low-grade albuminuria and cardiovascular risk: what is the evidence? Clin Res Cardiol 2007;96:247-257
13. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869 (Pubitemid 34940825)
14. Federal Institute for Medicinal Products and Medical Devices. German Drug Law (Arzneimittelgesetz - AMG) of the Federal Republic of Germany. Available at: http://www.bfarm.de/cln-030/nn-891668/SharedDocs/Publikationen/EN/BfArM/ service/AMG-en,templateId=raw,property=publicationFile.pdf/AMG-en.pdf [Last accessed 9 February 2009]
15. Federal Institute for Medicinal Products and Medical Devices (BfArM). Recommendations for the Planning, Execution and Evaluation of Post-Marketing Surveillance Studies (Bekanntmachung über die Zulassung und Registrierung von Arzneimitteln - Empfehlungen zur Planung und Durchführung von Anwendungsbeobachtungen). Bonn, 1998. Available at: http://www.dzkf.de/heft/ 1999-1-2/AWBs.htm [Last accessed 9 February 2009]
16. German Association of Research-based Pharmaceutical Companies (Verband der forschenden Arzneimittelhersteller VfA). Rules for publication of post-marketing surveillance studies. Available at: http://www.vfa.de/en/ articles/art-2007-11-002.html [Last accessed 9 February 2009]
17. Fernandez Fernandez I, Paez Pinto J, Hermosin Bono T, et al. Rapid screening test evaluation for microalbuminuria in diabetes mellitus. Acta Diabetol 1998;35:199-202 (Pubitemid 29047934)
18. Piehlmeier W, Renner R, Schramm W, et al. Screening of diabetic patients for microalbuminuria in primary care - The PROSIT-Project. Proteinuria Screening and Intervention. Exp Clin Endocrinol Diabetes 1999;107:244-251 (Pubitemid 29322137)
19. Soffer BA, Wright Jr JT, Pratt JH, et al. Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension 1995;26:112-117
20. Naidoo DP, Sareli P, Marin F, et al. Increased efficacy and tolerability with losartan plus hydrochlorothiazide in patients with uncontrolled hypertension and therapy-related symptoms receiving two monotherapies. Adv Ther 1999;16:187-199
21. Flack JM, Saunders E, Gradman A, et al. Antihypertensive efficacy and safety of losartan alone and in combination with hydrochlorothiazide in adult African Americans with mild to moderate hypertension. Clin Ther 2001;23:1193-1208 (Pubitemid 32804114)
22. Gradman AH, Brady WE, Gazdick LP, et al. A multicenter, randomized, double-blind, placebo-controlled, 8-week trial of the efficacy and tolerability of once-daily losartan 100 mg/hydrochlorothiazide 25 mg and losartan 50 mg/hydrochlorothiazide 12.5 mg in the treatment of moderate-to-severe essential hypertension. Clin Ther 2002;24:1049-1061 (Pubitemid 34833229)
23. Salerno CM, Demopoulos L, Mukherjee R, et al. Combination angiotensin receptor blocker/hydrochlorothiazide as initial therapy in the treatment of patients with severe hypertension. J Clin Hypertens (Greenwich) 2004;6:614-620
24. Oparil S, Aurup P, Snavely D, et al. Efficacy and safety of losartan/hydrochlorothiazide in patients with severe hypertension. Am J Cardiol 2001;87:721-726 (Pubitemid 32209085)
25. Coca A, Sobrino J, Soler J, et al. Trough-to-peak ratio, smoothness index, and circadian blood pressure profile after treatment with once-daily fixed combination of losartan 100 and hydrochlorothiazide 25 in essential hypertension. J Cardiovasc Pharmacol 2002;39:824-833 (Pubitemid 34538812)
26. Förster A, Smolka W, Jung C, et al. Fixed-dose combination of losartan/hydrochlorothiazide 100mg/25mg: safety and efficacy on office and 24-h blood pressure [German]. MMW Fortschr Med 2007;149:111-118
27. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003 (Pubitemid 34286536)
28. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-3421
29. Ryden L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007;28:88-136 (Pubitemid 46137814)
30. Zanchetti A, Hansson L, Clement D, et al. Benefits and risks of more intensive blood pressure lowering in hypertensive patients of the HOT study with different risk profiles: does a J-shaped curve exist in smokers? J Hypertens 2003;21:797-804
31. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-788 (Pubitemid 37093919)
32. Lubsen J, Wagener G, Kirwan B, et al. ACTION (A Coronary disease Trial Investigating Outcome with Niefedipine GITS) investigators. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial. J Hypertens 2005;23:642-648
33. Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004;292:2217-2225 (Pubitemid 39473159)
34. Diehm CD, Pittrow D, Allenberg J, et al. Metabolic syndrome and peripheral arterial disease as indicators for increased cardiovascular risk [German]. Deutsche Med Wochenschr 2007;132:15-20 (Pubitemid 46406240)
35. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-153
36. Arima H, Chalmers J, Woodward M, et al. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. J Hypertens 2006;24:1201-1208 (Pubitemid 43772329)
37. O'Connor PJ. Overcome clinical inertia to control systolic blood pressure. Arch Intern Med 2003;163:2677-2678 (Pubitemid 37517407)
38. Phillips L, Branch W, Cook C, et al. Clinical inertia. Ann Intern Med 2001;135:825-834 (Pubitemid 33051266)
39. Bestehorn K, Smolka W, Schmieder R, et al. Improvement of hypertension management by structured physician education and feedback system: cluster randomised trial. Internal study report, 2 February 2008. MSD Haar, Germany
40. Pittrow D, Kirch W, Bramlage P, et al. Patterns of antihypertensive drug utilization in primary care. Eur J Clin Pharmacol 2004;60:135-142 (Pubitemid 38626444)
41. Law MR, Wald NJ, Morris JK, et al. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. Brit Med J 2003;326:1427-1440 (Pubitemid 36776153)
42. Bramlage P, Pittrow D, Kirch W. The effect of irbesartan in reducing cardiovascular risk in hypertensive type 2 diabetic patients: an observational study in 16 600 patients in primary care. Curr Med Res Opin 2004;20:1625-1631 (Pubitemid 39457550)
43. Moen MD, Wagstaff AJ. Losartan: a review of its use in stroke risk reduction in patients with hypertension and left ventricular hypertrophy. Drugs 2005;65:2657-2674 (Pubitemid 43050959)
44. Lakshman MR, Reda DJ, Materson BJ, et al. Diuretics and beta-blockers do not have adverse effects at 1 year on plasma lipid and lipoprotein profiles in men with hypertension. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Arch Intern Med 1999;159:551-558 (Pubitemid 29133879)
45. Weir MR, Moser M. Diuretics and beta-blockers: is there a risk for dyslipidemia? Am Heart J 2000;139:174-183